V ascular calcification is a frequent complication of vascular disease, such as diabetes mellitus, renal disease, and atherosclerosis, and is associated with an increased risk of cardiovascular and all-cause mortality. 1 It is a regulated process with strong similarities to bone formation driven by osteochondrogenic progenitor cells. 1 Vascular medial cells functioning as adult mesenchymal stem cells or smooth muscle cells (SMCs) transdifferentiating into multipotent cells are thought to be the major contributors of such progenitor cells. 1, 2 Interestingly, endothelial cells (ECs) have been reported to contribute osteoblastic cells in fibrodysplasia ossificans progressiva, a rare genetic disorder linked to mutations in the activin receptor-like kinase 2 (ALK2), a receptor for bone morphogenetic protein 4 (BMP4). 3 Fibrodysplasia ossificans progressiva is characterized by the development of soft tissue masses outside major vessels, in which ECs undergo endothelial-mesenchymal transitions (EndMT) and contribute cells to the ectopic ossification. 4 Furthermore, prostate tumor ECs have been shown to undergo mesenchymal-like transitions and osteochondrogenic differentiation, 5 mitral valve leaflets contain ECs with osteogenic potential, 6 and high glucose can induce transdifferentiation into chondrocyte-like cells in human aortic ECs. 7 However, it is not known whether the arterial endothelium can act as a source of osteoprogenitor cells in vascular calcification, a frequent complication of vascular disease.
BMP signaling is known to promote vascular calcification, and others and we have reported that limiting vascular BMP signaling decreases both atherosclerotic lesion and diabetic medial calcification. [8] [9] [10] [11] Endothelial expression of BMP2 and 4 is highly responsive to pathological stimuli, such as disturbed flow, increased oxidative stress, inflammation, and hyperglycemia, 12, 13 which may contribute to calcification. 1, 9 In diabetes mellitus, there is also a differential induction of BMP2 and BMP4 in the vascular wall; BMP2 is induced in the vascular media, where it may have an osteoinductive effect, whereas BMP4 is preferentially induced in the endothelium. 9 Activation of BMP signaling leads to an induction of BMP-inhibitors, 14, 15 which provide negative feedback whereas the presence of a Mgp transgene increases the MGP induction in response to BMP, enhancing the regulation of the BMP activity. 8, 9 Here, we demonstrate that endothelium may be a source of multipotent osteoprogenitor cells in vascular calcification that occurs in the setting of high BMP activity in mice lacking MGP and in diabetic mice with high vascular BMP expression.
Methods
See Online Data Supplement for further details on fluorescence-activated cell sorting (FACS) analysis, immunostaining, transmission electron microscopy, and analytic procedures.
Animals

Mgp
+/− mice on C57BL/6J background were obtained from Dr Cecilia Giachelli (University of Washington, Seattle) with the permission of Dr Gerard Karsenty (Columbia University, New York) and have been backcrossed >10×. Ins2
Akita/+ mice (strain C57BL/6-Ins Akita /J, stock # 003548), which are heterozygous for a mutation in 1 allele of the insulin-2 gene, 20 
Cell Culture and SiRNA Transfection
Human aortic ECs (HAECs) were prepared and cultured as described. 15, 24 Transient transfections of HAEC with siRNA were performed with Lipofectamine 2000 (Invitrogen) using 60 nmol/L siRNA as described. 15 Three separate siRNAs to each protein (Silencer predesigned siRNA; Ambion) and scrambled siRNA with the same nucleotide content were tested. The siRNA that provided the most efficient inhibition (90%-95%), as determined by real-time PCR and immunoblotting or immunostaining, was used for experiments. Silencer predesigned siRNAs were obtained for MGP, core binding factor-α1 (Cbfa1), and SM22α. Treatments were initiated 12 to 24 hours after the start of transfection, after removal of the transfection agent. For treatment, BMP2, BMP4, Noggin (all from R&D Systems), glucose, and osteogenic medium were added as indicated in the text.
Fluorescence-Activated Cell Sorting
FACS was performed as detailed in Online Data Supplement.
RNA Analysis
Reverse transcriptase-PCR and real-time PCR were performed as described. 15 GAPDH was used as a control gene. Primers and probes for cluster of differentiation (CD) 31, vascular endothelial (VE)-cadherin, fetal liver kinase 1, Sox2, Nanog, Oct3/4, Cbfa1, and Osterix were obtained from Applied Biosystems as part of TaqMan Gene Expression Assays.
Immunoblotting
Immunoblotting was performed as described. 25, 26 Equal amounts of tissue or cellular protein were used. Tissues were collected at 4 weeks for Mgp −/− mice and controls, and at 35 to 40 weeks for mice with the Ins2 Akita mutation and controls. Blots were incubated with specific antibodies to CD31 (300 ng/mL; Cell Signaling Technology), VEcadherin (400 ng/mL; Santa Cruz Biotechnology), fetal liver kinase 1 (200 ng/mL; Santa Cruz Biotechnology), Sox2 (200 ng/mL; Cell Signaling), Nanog (400 ng/mL; BD Biosciences Pharmingen), Oct3/4 (200 ng/mL; R&D Systems), Cbfa1 (500 ng/mL; Oncogene Research Products; Osterix), SM22α (200 ng/mL; Santa Cruz Biotechnology), and α-SM actin (αSMA; 200 ng/mL; R&D Systems). β-Actin (1:5000 dilution; Sigma-Aldrich) was used as loading control.
Immunostaining
The tissues were collected at 4 weeks for Mgp −/− mice and 35 to 40 weeks for mice with the Ins2 Akita mutation, and the proximal descending aorta was used for tissue sections (Online Figure I, left) . We did not detect any particular areas that consistently showed more calcification than others in the mice that were included in this study. The calcification in the Mgp −/− mice was very extensive and uniform (Online Figure I, right) . The tissue sections were fixed in 4% paraformaldehyde and processed as described. 9 Cultured cells were grown in chamber slides and fixed in 4% paraformaldehyde for 30 minutes, permeabilized with 0.1% Triton X-100, and blocked with 1% goat serum and 1% bovine serum albumin in Tris-buffered saline, and incubated overnight. The cells were immunostained using the same protocol as the tissues.
Immunofluorescence was performed as described in the Online Data Supplement. 9 We used specific antibodies for CD31 (Millipore), von Willebrand factor (vWF; Dako), Cbfa1 and Osterix (Oncogene Research Products), SM22α (Santa Cruz Biotechnology), αSMA and Oct3/4 (R&D Systems), Sox2 (Cell Signaling), Nanog (BD Pharmingen and eBioscience), GFP (Abcam), and MGP (Dr Reidar Wallin, Wake Forest University). The nuclei were stained with 4′,6-diamidino-2-phenylindole (Sigma-Aldrich). 24 Nonspecific IgG was included as a primary antibody control in all experiments, where it showed no significant staining, which has been included in selected figures.
Transmission Electron Microscopy
Aortic tissue samples were analyzed by transmission electron microscopy as described in Online Data Supplement. 
Histochemical Staining
Histochemical staining for alkaline phosphatase activity and mineral (Alizarin Red and Von Kossa) was performed as previously described.
9
Analytic Procedures
Samples were analyzed as described in Online Data Supplement.
Statistical Analysis
Data were analyzed for statistical significance by 2-way ANOVA with post hoc Tukey analysis using the GraphPad Instat 3.0 software (GraphPad Software, San Diego, CA). P values <0.05 were considered significant. All experiments were repeated a minimum of 3×.
Results
Endothelial Origin of Osteogenic Cells in Mgp −/−
Calcified Aortas
To determine whether the endothelium contributes osteoprogenitor cells to vascular calcification, we first compared the aortic endothelium in wild-type and Mgp −/− mice, a well-known model of vascular calcification. 19 These mice are known to be tachycardic 19 with a very high pulse wave velocity in the aorta at rest, 27 presumably from the dramatic increase in aortic calcium, 8 and endothelial dysfunction as evidenced by minimal inflammatory response to hyperlipidemia, 8 and the formation of arteriovenous malformations. 17 In Mgp −/− mice, the endothelium was highly abnormal as visualized by phase contrast and transmission electron microscopy; a mixture of cells largely replaced normal ECs, including chondroblast-like cells ( Figure 1A , the magnification is the same in all panels). Occasionally, EC-like cells were detected that seemed to have detached from the internal elastic lamina and were surrounded by abnormal matrix ( Figure 1A , bottom). The abnormalities were associated with increased aortic expression of EC lineage markers CD31, VE-cadherin, and fetal liver kinase 1, as determined by real-time PCR and immunoblotting ( Figure 1B) . Furthermore, CD31 and vWF expression was detected deep in the calcified media ( Figure 1B) , and immunostaining showed ; Tie2-Gfptg mice. Scale bars, 100 µm. 4′,6-Diamidino-2-phenylindole (DAPI; blue) was used to visualize nuclei. Nonspecific IgG control showed no staining. Vessel lumen faces upward in the photos unless otherwise indicated. DIC indicates differential interference contrast; H&E, hematoxylin and eosin; IEL, internal elastic lamina; and Lu, lumen.
coexpression of CD31 and vWF, respectively, with osteogenic markers Cbfa1 and Osterix ( Figure 1C ). The Mgp −/− aortas contained ≈28.8% cells that double-stained for CD31 and Cbfa1, as determined by FACS after dispersion of aortic cells ( Figure 1D ) and exclusion of CD45+ cells, which may represent CD31+ leukocyte populations. The efficiency of the CD45 presorting was checked with FACS (Online Figure II) . Cells that coexpressed CD31 and a bone marker also seemed to penetrate into the media ( Figure 1E) .
To confirm the endothelial origin of the osteogenic cells, we performed lineage tracing as described. 3 We crossed Tie2-Gfptg reporter mice with 
Multipotent Marker Expression in Mgp −/−
Endothelium
MGP is an efficient inhibitor of BMP4, 16 which can activate the ALK2 receptor and promote EndMT in ECs. 3 Therefore, we examined expression of multipotent markers Sox2, Nanog, and Oct3/4 in the Mgp −/− aortas. The results revealed an increase of all 3 markers by immunoblotting (Figure 2A, left) . The multipotent markers were detected in the cell nuclei by immunostaining, whereas the EC marker CD31 was found in the cell membranes of the same cells (Figure 2A, right) . We also examined multipotent markers in the aortas of Mgp 
Time Course of Multipotent and Osteogenic Marker Expression in Mgp −/− Aorta
To better understand the time course of the aortic changes, we collected aortas from Mgp −/− mice on postnatal days (P) 2, 4, 6, 8, 10, 15, 20, and 30 and examined the aortic tissues by hematoxylin and eosin staining, real-time PCR, and immunostaining. The hematoxylin and eosin staining showed mild abnormalities on P8 and gross calcification on P15 to 30, which seemed to start on the endothelial side of the vessel wall ( Figure 3A ; see Online Figure III for higher magnification). Real-time PCR showed that expression of EC markers CD31 and VE-cadherin increased as early as P4 in the Mgp −/− mice and peaked at P15 ( Figure 3B ). The expression of Sox2, Nanog, and Oct3/4 increased on P4 to 6 and peaked on P15 similar to the EC markers, whereas the expression of Cbfa1 and Osterix increased on P8 and had not reached a clear peak on P30 ( Figure 3B ). The expression of all markers was unchanged in the wild-type mice. The time course of MGP expression in wild-type mice was similar to that of the EC and multipotency markers in the Mgp −/− mice, whereas the BMP4 expression was similar in both mice ( Figure 3B ). MGP was not detected in the Mgp −/− mice as expected. Immunostaining revealed mild CD31 expression in the media of Mgp −/− mice on P6, which increased through P30 ( Figure 4A ). Sox2 and Osterix expression appeared on P8 and P10, respectively, and increased through P30 (Figure 4B and  4C) . No significant change in CD31 expression was detected in the wild-type endothelium, and Sox2 or Osterix were not detected. Overall, the data support that CD31 and the multipotency markers increase before the bone markers, suggesting a temporal relationship. Interestingly, the finding that the expression pattern of CD31 and Sox2 resembles that of MGP in the wild-type mice suggests that MGP is required during this time period to promote EC differentiation.
Endothelial Origin of Osteogenic and Multipotent Cells in Aortas of Diabetic Ins2
Akita/+ Mice
We previously showed increased aortic BMP activity in diabetic Ins2 Akita/+ mice associated with aortic osteogenesis and calcium accumulation. 9 These mice are known to develop diabetic cardiomyopathy but heart rate and blood pressure remain largely unchanged. 28, 29 In addition, there were no significant differences in serum phosphate and total cholesterol between wild-type and Ins2
Akita/+ mice (Online Table I ). To determine whether the endothelium was a source of multipotent cells in the Ins2
Akita/+ mice, we first demonstrated expression of CD31 and vWF in areas of calcification in the vascular media ( Figure 5A ). Immunostaining revealed coexpression of CD31 and vWF with Cbfa1 and Osterix in the calcified areas ( Figure 5B) , and FACS analysis showed that 19.2% of the aortic cells double-stained for CD31 and Cbfa1 after exclusion of CD45+ cells ( Figure 5C ). The Ins2 Akita/+ mice were then crossed with the Tie2-Gfptg mice for lineage tracing. When examining the aortas of the Ins2 Akita/+ ; Tie2-Gfptg mice, we detected GFP-positive cells in the endothelium and the media ( Figure 5D ), which coexpressed Cbfa1 and Osterix ( Figure 5E ), suggesting that the osteogenic cells were EC derived. The aortic expression of Sox2, Nanog, and Oct3/4 was also increased in both Ins2
Akita/+ and Ins2
Akita/+ ; Tie2-Gfptg mice, as determined by immunoblotting ( Figure 6A ), and immunostaining ( Figure 6B and 6C ). FACS analysis showed that 21.5% of the cells coexpressed CD31 and Sox2 after exclusion of CD45+ cells ( Figure 6D ). Figure 6E and 6F), supporting that the enhanced aortic expression of MGP also reduced multipotency in the diabetic aortas. Immunostaining showed that increased MGP limited CD31 expression to the endothelium ( Figure 6G ).
Enhanced MGP Expression Limits Multipotency in Aortas of
ECs Acquire Multipotency and Susceptibility to Osteoinduction After Depletion of MGP
To examine the effect of loss of MGP on multipotency in vitro, HAECs were transfected with MGP siRNA or scrambled control siRNA. More than 99.5% of the HAECs expressed CD31 by FACS (data not shown). The siRNA transfection decreased MGP protein levels to <10% to 20% of normal levels as shown by immunostaining after 20 to 24 hours (Online Figure IV) . We also combined the siR-NA transfection with treatment of the cells with BMP4 (40 ng/mL), Noggin (a BMP-inhibitor; 200 ng/mL), or BMP4 and Noggin, added 12 hours after the transfection. The results showed that expression of Sox2, Nanog, and Oct3/4 increased after MGP depletion, as determined by immunoblotting ( Figure 7A, lanes 1-2) . BMP4 further increased expression of Sox2, Nanog, and Oct3/4, whereas Noggin abolished the marker expression ( Figure 7A , lanes 3-6). Added together, BMP4 and Noggin were similar to control ( Figure 7A , lanes 7-8). We confirmed that BMP4 increased multipotency in MGP-depleted HAEC by FACS analysis. Coexpression of the stem cell markers stage-specific embryonic antigen-3 and stage-specific embryonic antigen-4, and CD31 was observed in MGP-depleted HAECs ( Figure 7B , left). BMP4 increased the population of stage-specific embryonic antigen-3+/CD31+ cells from 18.9% to 57.1%, and the population of stage-specific embryonic antigen-4+/ CD31+ cells from 22.8% to 60.1% ( Figure 7B , right).
To test for osteogenic differentiation in MGP-depleted HAECs, we treated with osteogenic medium, BMP2 (200 ng/mL), or a combination of osteogenic medium and BMP2 for 4 days starting the day after transfection. Alternatively, we replaced the osteogenic medium with glucose (22 nmol/L) to mimic hyperglycemia. Expression of Sox2, Nanog, and Oct3/4 increased after MGP depletion, but decreased when the osteoinduction was strongly promoted by the combination of BMP2 and osteogenic medium or glucose, as determined by immunoblotting ( Figure 7C and 7E, top 3 panels). Expression of the osteogenic markers, Cbfa1 and Osterix, as well as the early SMC markers SM22α and αSMA, increased in all 3 conditions (Figure 7C and 7E, bottom). Interestingly, expression of SM-myosin heavy chain, a late SMC marker, was not detected in any of the samples ( Figure 7C and 7E, bottom) . Alkaline phosphatase activity, an early osteogenic marker, and calcium accumulation, a late osteogenic marker, increased in the MGP-depleted HAECs after 7 and 14 days of treatment, respectively, as determined by alkaline phosphatase and mineral staining (Alizarin Red and Von Kossa; Figure 7D and 7F). Altogether, the results are consistent with the in vivo experiments, and support that endothelial MGP depletion may cause multipotency and osteoinduction.
SM22α Expression Is Not Required for Expression of Osteogenic Markers in ECs
Speer et al 2 
recently reported that osteochondrogenic cells in Mgp
−/− aortas transdifferentiate from vascular SMCs on the basis of lineage tracing using SM22α-Cre; R26R-LacZ mice. Sun et al 30 similarly used SM22α-Cre mice to specifically delete Cbfa1 (Runx2) in SM22α-expressing cells, and concluded that SMC-derived Cbfa1 regulated vascular calcification. Although SM22α is considered an early marker of SMCs, it is also expressed in myofibroblasts, pericytes, and after EndMT. [31] [32] [33] To determine whether SMC markers ; Tie2-Gfptg mice. Scale bars, 100 µm. 4′,6-Diamidino-2-phenylindole (DAPI; blue) was used to visualize nuclei. Nonspecific IgG control showed no staining. Vessel lumen faces upward in the photos.
were induced in the MGP-deficient ECs, we costained aortas from Mgp −/− and Ins2 Akita/+ mice with antibodies to CD31 and SM22α or αSMA. The results showed coexpression of CD31 and SM22α or αSMA in both aortas ( Figure 8A ). We then tested whether SM22α was required for osteoinduction in HAECs in vitro, and conversely, whether Cbfa1 was required for expression of early SMC markers. HAECs were transfected with scrambled control siRNA or MGP siRNA, and MGP siRNA was cotransfected with SM22α or Cbfa1 siRNA. The cells were treated with osteogenic medium and BMP2 as before, and expression of Cbfa1, Osterix, SM22α, αSMA, and SM-myosin heavy chain was determined by immunoblotting. The depletion of Cbfa1 did not affect expression of SM22α or αSMA, and depletion of SM22α did not affect expression of Cbfa1 or Osterix ( Figure 8B ). No expression of SM-myosin heavy chain was detected in any of the samples, suggesting that the cells do not undergo late SMC differentiation. The results suggested that expression of SM22α is not required for the ECs to undergo osteogenic differentiation.
Discussion
In this report, we demonstrate that the vascular endothelium acts as a source of multipotent cells that may contribute to vascular calcification in states of high BMP activity, such as lack of the BMP-inhibitor MGP 17 and hyperglycemia. 9 Vascular calcification could, therefore, be considered an acquired stem cell disorder in these settings.
It has previously been shown that BMP4 binds to the ALK2 receptor, which allows for EndMT and the generation of cells that are able to undergo osteoinduction. Fibrodysplasia ossificans progressiva, characterized by ectopic soft tissue calcification, is caused by mutations in ALK2 that render the receptor constitutively active. 3 In our study, ALK2 is activated in the aortic endothelium of both Mgp −/− and the Ins2
Akita/+ mice, in the Mgp −/− mice because of lack of BMP4 inhibition, and in the Ins2
Akita/+ mice because of induction of BMP4 and ALK2. 9, 17 However, the resulting EndMT and multipotent cells seem to be restricted to the artery wall in these mice, 9, 19 whereas fibrodysplasia ossificans progressiva lesions are found outside the major vessels. 3, 4, 34 In the diabetic mice, the increase in BMP4/ALK2 activity overwhelms the available BMP-inhibition, which can be enhanced by increasing the expression of MGP through a transgene. 9 The increase in MGP led to a limitation of vascular calcification in the previous study, 9 and was consistent with the decrease in the expression of multipotency markers seen in the current study. EndMT have also been reported in ECs derived from the mitral valve leaflets, 6 and in HAECs in vitro, 7 which together with our data support an important role for the endothelium in the development of cardiovascular calcification.
Mechanistically, BMP4 is known to induce expression of MGP in ECs, 15 which provides negative feedback inhibition for BMP2 and BMP4, 16 and regulates BMP-induced events in the vascular wall. 8, 9 Such activities may include the promotion of multipotency, EC proliferation and differentiation, and osteogenic induction. 13, 17, [35] [36] [37] BMP4 alone was sufficient to stimulate osteogenic induction in human umbilical vein ECs and human cutaneous microvascular ECs, 3 whereas MGP depletion, preferably in combination with BMP treatment, induced osteogenic differentiation in the HAECs in our experiments. The optimal balance between BMP4 treatment and MGP depletion required for osteoinduction may vary between different types of cultured ECs, and is not yet fully elucidated.
We used the Tie2-Gfp transgene for endothelial lineage tracing an approach similar to that used by other investigators. 3 Expression of Tie2 and VE-cadherin, both commonly used for lineage tracing and excision in the endothelium, has been detected in small subpopulations of hematopoietic cells and in areas of endocardial-mesenchymal transformation in the embryonic atrioventricular canal and outflow tract. 38, 39 Although it is impossible to exclude, it is less likely that hematopoietic cells, such as monocytes, would directly transition to osteoprogenitor cells in these studies, especially in the Mgp −/− aortas where the expression of inflammatory and monocyte markers is minimal or undetectable. 8 Furthermore, even if the exclusion of CD45+ cells before FACS analysis of aortic cells from Mgp −/− and Ins2 Akita/+ may have removed a small number of CD45+CD31+ leukocytic cells, 20% to 30% of the analyzed cells still coexpressed CD31 and Cbfa1 or Sox2. Finally, our lineage tracing was accompanied by costaining of EC and multipotency or osteogenic markers, which gave similar results, supporting our conclusions. Overall, this supports that osteogenic cells can be derived from the vascular endothelium.
The goal of our study is to determine whether ECs can give rise to osteogenic cells. Thus, an analysis of the origin of the ECs is beyond the scope of this study. The ECs may be derived locally or from EC progenitors from the bone marrow. Indeed, Cho et al 40 recently showed that bone marrow-derived cells easily gained access to atherosclerotic aortic wall in Apoe −/− mice, and Naik et al 41 estimated that bone marrow-derived cells account for ≈20% of Cbfa1-positive cells in the calcified atherosclerotic vessels of Apoe −/− mice. However, none of these investigators explored whether the bone marrowderived cells differentiated into ECs or EC-like cells.
It has been proposed that osteoblastic cells in the media are derived from SMCs on the basis of lineage tracing using SM22α-LacZ transgenic mice and Cbfa1 (Runx2) deletion in SM22α-expressing cells.
2, 30 The osteoblastic cells could also . Expression of Cbfa1, Osterix (OSX), SM22α, αSMA, and SM-myosin heavy chain (SM-MHC) was determined by immunoblotting. β-Actin was used as control. Scale bars, 100 µm. 4′,6-Diamidino-2-phenylindole (DAPI; blue) was used to visualize nuclei. Vessel lumen faces upward in the photos.
be derived from a new type of multipotent vascular stem cells recently identified in the blood vessel wall, which become proliferative and undergo SMC and osteochondrogenic cell differentiation after vascular injury. 42 In our studies, MGP depletion in the HAECs induced expression of both early SMC markers (SM22α and αSMA) and osteogenic markers (Cbfa1 and Osterix). However, no expression of the late SMC marker SM-myosin heavy chain was detected. Furthermore, depletion of both MGP and SM22α still allowed for the induction of the osteogenic markers, suggesting that SM22α is not required for osteoinduction in these cells. Thus, it is possible that osteoprogenitor cells derived from the endothelium do not express SM22α and would not be detected when the SM22α promoter is used for lineage tracing. Alternatively, SM22α-expressing cells in the vascular wall, known to contribute to vascular calcification, may be the result of prior EndMT in the vascular endothelium.
Induction of multipotency by BMP in endothelium could be an important physiological mechanism during development and after injury. Such activation would provide a local source of stem cells that could promote growth or healing of the vasculature itself, or tissue-specific cell differentiation depending on local cues. It would be consistent with the concept of stemness being a function of the local context. 43 Overall, our data support that diseased endothelium with excess BMP activity may contribute osteoprogenitor cells to vascular calcification.
